Pradaxa Litigations ended – parties agreed on settlement

Boehringer Ingelheim has reached a comprehensive settlement to resolve the remaining claims pending in the Pradaxa litigation. The settlement covers all currently pending cases in state and federal courts as well as all known unfiled claims.  

With the most recent favorable judicial rulings, Boehringer Ingelheim expects the Pradaxa litigation will be concluded in its entirety. Time and again, Pradaxa’s benefits and established safety profile have been confirmed.  Our first priority is the safety of patients who are prescribed our medicines. We remain focused on our core mission of delivering innovative and life-saving treatments to patient.